Xilio Therapeutics initiated a Phase 1/2 clinical trial for XTX501, a novel PD-1/masked IL-2 bispecific antibody targeting metastatic non-small cell lung cancer and other solid tumors. The drug aims to improve immune response while reducing side effects common to IL-2 therapies. Xilio also advanced two other masked T cell engager programs targeting gastrointestinal and prostate cancers, with IND applications planned for late 2027. Financially, the company reported a net loss of $5.9 million in Q3 2026 but has $122.2 million in cash, sufficient to fund operations into early 2028.
Xilio Therapeutics' Q3 2026 financial results and pipeline updates provide context for readers. For those following the health sector, here is Pluang's market snapshot as of Nov 10, 2026 18:42 WIB: out of 150 priced US health stocks, 85 rose and 56 fell. Among notable movers, BioNano Genomics Inc (BNGO) rose 1.72% to USD 1.18 with a typical hold time of 53 days and 100% sell order activity, while Revvity Inc (RVTY) increased 1.53% to USD 163.18 with a much shorter hold time of 14 days and also 100% sell orders. LifeStance Health Group Inc (LFST) gained 1.44% to USD 14.81 with a 12-day typical hold time.
Duke Robotics has entered a strategic collaboration with Greek security firm CRONOS to commercialize its Insulator Cleaning Drone (IC Drone) technology in Greece. This partnership leverages CRONOS's strong presence in Greece's critical infrastructure...
Alm. Brand A/S repurchased 1,369,397 shares between November 3 and 9, 2026, at an average price of DKK 17.46 per share. This is part of their announced buy-back program totaling up to DKK 593 million, aiming to reduce the number of outstanding shares...
H&R Block has launched the Emerald Advance Loan, a fixed-rate short-term loan up to $1,750 with a 35.90% APR, designed to help families cover year-end expenses without monthly payments. Borrowers repay the loan in full by March 31, 2027, with no impa...
Novartis has secured first place in the 2026 Access to Medicine Index, maintaining its lead since 2024 by excelling across all assessed technical areas, including governance, R&D, and product delivery. The company scored 3.86 out of 5 overall, with a...
Viasat has been awarded a $450 million IDIQ contract by the U.S. Space Force to support the design, development, and sustainment of the Space Data Network Backbone (SDN-B) mission operations center. This network aims to provide resilient, high-capaci...
